Global epidemiology of occult hepatitis B virus infections in blood donors, a systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
02
2022
accepted:
28
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
25
8
2022
Statut:
epublish
Résumé
This study aimed to assess the global prevalence of occult hepatitis B in blood donors. We searched PubMed, Web of Science, Global Index Medicus, and Excerpta Medica Database. Study selection and data extraction were performed by at least two independent investigators. Heterogeneity (I2) was assessed using the χ2 test on the Cochran Q statistic and H parameters. Sources of heterogeneity were explored by subgroup analyses. This study is registered with PROSPERO, number CRD42021252787. We included 82 studies in this meta-analysis. The overall prevalence of OBI was 6.2% (95% CI: 5.4-7.1) in HBsAg negative and anti-HBc positive blood donors. Only sporadic cases of OBI were reported in HBsAg negative and anti-HBc negative blood donors. The overall prevalence of OBI was 0.2% (95% CI: 0.1-0.4) in HBsAg negative blood donors. The prevalence of OBI was generally higher in countries with low-income economic status. The results of this study show that despite routine screening of blood donors for hepatitis B, the transmission of HBV by blood remains possible via OBI and/or a seronegative window period; hence there is a need for active surveillance and foremost easier access to molecular tests for the screening of blood donors before transfusion.
Identifiants
pubmed: 35994469
doi: 10.1371/journal.pone.0272920
pii: PONE-D-22-03546
pmc: PMC9394819
doi:
Substances chimiques
DNA, Viral
0
Hepatitis B Antibodies
0
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0272920Subventions
Organisme : European & Developing Countries Clinical Trials Partnership
ID : EDCTP_TMA2019PF-2705
Pays : Netherlands
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Hepatol. 2014 Mar;60(3):515-22
pubmed: 24239777
Blood Transfus. 2009 Jul;7(3):174-82
pubmed: 19657480
J Hepatol. 1996 Nov;25(5):639-43
pubmed: 8938539
Asian J Transfus Sci. 2014 Jan;8(1):2-3
pubmed: 24678164
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
J Clin Microbiol. 2005 Jun;43(6):2991-3
pubmed: 15956441
Lancet. 1995 Jun 3;345(8962):1406-7
pubmed: 7539089
Lancet. 1990 Aug 11;336(8711):325-9
pubmed: 1697396
Lancet. 1988 Dec 3;2(8623):1273-6
pubmed: 2904005
Indian J Med Res. 2008 Feb;127(2):140-7
pubmed: 18403791
Transfusion. 2010 Feb;50(2):433-42
pubmed: 19843290
J Hepatol. 2008 Jun;48(6):1022-5
pubmed: 18436328
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Arch Virol Suppl. 1992;4:116-8
pubmed: 1450678
PLoS One. 2013 Nov 13;8(11):e79203
pubmed: 24236110
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Transfusion. 2007 Jul;47(7):1162-71
pubmed: 17581150
J Viral Hepat. 2014 Mar;21(3):153-62
pubmed: 24438677
Transfus Clin Biol. 2017 Sep;24(3):189-195
pubmed: 28673499
Lancet Infect Dis. 2002 Aug;2(8):479-86
pubmed: 12150847
Front Med (Lausanne). 2018 Feb 21;5:29
pubmed: 29515997
Clin Chem Lab Med. 2010;48(1):23-9
pubmed: 19919328
Vox Sang. 2004 Feb;86(2):83-91
pubmed: 15023176
Dig Liver Dis. 2013 Mar;45(3):238-44
pubmed: 23146778
J Hepatol. 2009 Oct;51(4):798-809
pubmed: 19615780
J Hepatol. 2008 Oct;49(4):652-7
pubmed: 18715666
J Infect. 2005 Oct;51(3):263
pubmed: 16125778
Curr Opin Hematol. 2011 Nov;18(6):461-6
pubmed: 21912252
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
N Engl J Med. 1999 Jul 1;341(1):22-6
pubmed: 10387938
JGH Open. 2020 Aug 26;4(5):800-807
pubmed: 33102748
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
Transfusion. 2009 Apr;49(4):757-64
pubmed: 19171000
Transfus Sci. 1997 Mar;18(1):49-53
pubmed: 10174292
Semin Immunopathol. 2013 Jan;35(1):39-52
pubmed: 22829332